Journal Home > Volume 11 , Issue 7
Nano Research 2018, 11(7): 3619-3635 https://doi.org/10.1007/s12274-017-1928-1
Research Article | Issue | Published: 02 August 2018

Efficiency against multidrug resistance by co-delivery of doxorubicin and curcumin with a legumain-sensitive nanocarrier

Show Author's Information Sen Lin1,2,3( ),  Peiling Xie1,  Mengmeng Luo1,  Qing Li2,3,  Ling Li1,  Jinzhao Zhang1,  Qinxiang Zheng1,  Hao Chen1,3,  Kaihui Nan1,3( )
School of Ophthalmology & Optometry and Eye HospitalWenzhou Medical UniversityWenzhou325027China
Wenzhou Institute of Biomaterials and EngineeringChinese Academy of ScienceWenzhou325000China
School of Biomedical and EngineeringWenzhou Medical UniversityWenzhou325027China
Keywords:
curcumin, multidrug resistance, legumain, doxorubicin, co-delivery nanoparticle
Cite this article:
Lin S, Xie P, Luo M, et al. Efficiency against multidrug resistance by co-delivery of doxorubicin and curcumin with a legumain-sensitive nanocarrier. Nano Research, 2018, 11(7): 3619-3635. https://doi.org/10.1007/s12274-017-1928-1
Download citation
EndNote(RIS)
BibTeX

545

Views

50

Downloads

Citations

29

Crossref

N/A

WoS

30

Scopus

5

CSCD

Abstract Full text Electronic supplementary material About this article

Multidrug resistance proteins (MDRPs), which are implicated in the mediation of multidrug resistance in tumors, represent the main obstacle to successful chemotherapy. As curcumin (Cur) exerts inhibitory effects on both the expression and function of MDRPs, a nanocarrier for the co-delivery of Cur and doxorubicin (DOX) was prepared to overcome MDR tumors through their synergistic effects. Owing to the overexpression of legumain in tumors, the release profile of DOX from this nanocarrier was designed to be legumain modulated, which was achieved by bridging DOX to a basic material (chitosan) with a legumain-sensitive peptide. Compared with nanoparticles that only contain DOX, the coadministration of DOX and Cur significantly inhibited multidrug resistance (P < 0.05) in a multidrug-resistant cancer cell model (MCF-7/ADR cell line), with cytotoxicity to normal cells (L929 cell line). Such inhibition could be ascribed to the increased DOX accumulation in the MCF-7/ADR nucleus. The co-delivery system exhibited good anticancer effects through prolonged circulation time, improved tumor-targeting efficiency, elevation of the tumor inhibition activity, and the suppression of MDRP expression. These data revealed the enormous potential of this co-delivery system for cancer therapy, especially in the later stages where multidrug resistance may develop.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Efficiency against multidrug resistance by co-delivery of doxorubicin and curcumin with a legumain-sensitive nanocarrier

Show Author's information Sen Lin1,2,3( ), Peiling Xie1, Mengmeng Luo1, Qing Li2,3, Ling Li1, Jinzhao Zhang1, Qinxiang Zheng1, Hao Chen1,3, Kaihui Nan1,3( )
School of Ophthalmology & Optometry and Eye HospitalWenzhou Medical UniversityWenzhou325027China
Wenzhou Institute of Biomaterials and EngineeringChinese Academy of ScienceWenzhou325000China
School of Biomedical and EngineeringWenzhou Medical UniversityWenzhou325027China

Abstract

Multidrug resistance proteins (MDRPs), which are implicated in the mediation of multidrug resistance in tumors, represent the main obstacle to successful chemotherapy. As curcumin (Cur) exerts inhibitory effects on both the expression and function of MDRPs, a nanocarrier for the co-delivery of Cur and doxorubicin (DOX) was prepared to overcome MDR tumors through their synergistic effects. Owing to the overexpression of legumain in tumors, the release profile of DOX from this nanocarrier was designed to be legumain modulated, which was achieved by bridging DOX to a basic material (chitosan) with a legumain-sensitive peptide. Compared with nanoparticles that only contain DOX, the coadministration of DOX and Cur significantly inhibited multidrug resistance (P < 0.05) in a multidrug-resistant cancer cell model (MCF-7/ADR cell line), with cytotoxicity to normal cells (L929 cell line). Such inhibition could be ascribed to the increased DOX accumulation in the MCF-7/ADR nucleus. The co-delivery system exhibited good anticancer effects through prolonged circulation time, improved tumor-targeting efficiency, elevation of the tumor inhibition activity, and the suppression of MDRP expression. These data revealed the enormous potential of this co-delivery system for cancer therapy, especially in the later stages where multidrug resistance may develop.

Keywords: curcumin, multidrug resistance, legumain, doxorubicin, co-delivery nanoparticle

References(62)

1

Kutanzi, K. R.; Yurchenko, O. V.; Beland, F. A.; Checkhun, V. F.; Pogribny, I. P. MicroRNA-mediated drug resistance in breast cancer. Clin. Epigenetics 2011, 2, 171-185.
DOI Google Scholar
2

Santos, S. A.; Paulo, A. Small molecule inhibitors of multidrug resistance gene (MDR1) expression: Preclinical evaluation and mechanisms of action. Curr. Cancer Drug Tar. 2013, 13, 814-828.
DOI Google Scholar
3

Singh, P.; Paul, K.; Holzer, W. Multi drug resistance: An obstacle to the successful chemotherapy of cancer—its mechanism and remedies via MDR modulators. Natl. Acad. Sci. Lett. 2005, 28, 365-372.
Google Scholar
4

Toppmeyer, D.; Seidman, A. D.; Pollak, M.; Russell, C.; Tkaczuk, K.; Verma, S.; Overmoyer, B.; Garg, V.; Ette, E.; Harding, M. W. et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin. Cancer Res. 2002, 8, 670-678.
Google Scholar
5

Burkhart, C. A.; Watt, F.; Murray, J.; Pajic, M.; Prokvolit, A.; Xue, C. Y.; Flemming, C.; Smith, J.; Purmal, A.; Isachenko, N. et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 2009, 69, 6573-6580.
DOI Google Scholar
6

Das, M.; Sahoo, S. K. Folate decorated dual drug loaded nanoparticle: Role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 2012, 7, e32920.
DOI Google Scholar
7

Qiu, Y.; Park, K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Delivery Rev. 2012, 64, 49-60.
DOI Google Scholar
8

Haugen, M. H.; Boye, K.; Nesland, J. M.; Pettersen, S. J.; Egeland, E. V.; Tamhane, T.; Brix, K.; Maelandsmo, G. M.; Flatmark, K. High expression of the cysteine proteinase legumain in colorectal cancer—implications for therapeutic targeting. Eur. J. Cancer 2015, 51, 9-17.
DOI Google Scholar
9

Liu, Y.; Goswami, R. K.; Liu, C.; Sinha, S. C. Chemically programmed bispecific antibody targeting legumain protease and αvβ3 integrin mediates strong antitumor effects. Mol. Pharmaceutics 2015, 12, 2544-2550.
DOI Google Scholar
10

Edgington, L. E.; Verdoes, M.; Ortega, A.; Withana, N. P.; Lee, J.; Syed, S. Bachmann, M. H.; Blum, G.; Bogyo, M. Functional imaging of legumain in cancer using a new quenched activity-based probe. J. Am. Chem. Soc. 2013, 135, 174-182.
DOI Google Scholar
11

Wang, L. N.; Chen, S.; Zhang, M. N.; Li, N.; Chen, Y. N.; Su, W. J.; Liu, Y. H.; Lu, D.; Li, S. L.; Yang, Y. X. et al. Legumain: A biomarker for diagnosis and prognosis of human ovarian cancer. J. Cell Biochem. 2012, 113, 2679-2686.
DOI Google Scholar
12

Dall, E.; Brandstetter, H. Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation. Proc. Nat. Acad. Sci. USA 2013, 110, 10940-10945.
DOI Google Scholar
13

Dall, E.; Fegg, J. C.; Briza, P.; Brandstetter, H. Structure and mechanism of an aspartimide-dependent peptide ligase in human legumain. Angew. Chem., Int. Ed. 2015, 54, 2917-2921.
DOI Google Scholar
14

Lin, S.; Deng, F. F.; Huang, P.; Li, L. L.; Wang, L.; Li, Q.; Chen, L.; Chen, H.; Nan, K. H. A novel legumain protease- activated micelle cargo enhances anticancer activity and cellular internalization of doxorubicin. J. Mater. Chem. B 2015, 3, 6001-6012.
DOI Google Scholar
15

Liu, Z.; Xiong, M.; Gong, J. B.; Zhang, Y.; Bai, N.; Luo, Y. P.; Li, L. Y.; Wei, Y. Q.; Liu, Y. H.; Tan, X. Y. et al. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat. Commun. 2014, 5, 4280.
DOI Google Scholar
16

Huang, Y. H.; Cole, S. P. C.; Cai, T. G.; Cai, Y. Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer. Oncol. Lett. 2016, 12, 11-15.
DOI Google Scholar
17

Shen, J. N.; He, Q. J.; Gao, Y.; Shi, J. L.; Li, Y. P. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: Performance and mechanism. Nanoscale 2011, 3, 4314-4322.
DOI Google Scholar
18

Tang, J.; Zhang, L.; Gao, H.; Liu, Y.; Zhang, Q.; Ran, R.; Zhang, Z.; He, Q. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity. Drug Deliv. 2016, 23, 1130-1143.
DOI Google Scholar
19

Li, J.; Wang, Y.; Zhu, Y.; Oupický, D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J. Control. Release 2013, 172, 589-600.
DOI Google Scholar
20

Li, J. M.; Zhang, W.; Su, H.; Wang, Y. Y.; Tan, C. P.; Ji, L. N.; Mao, Z. W. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-beta-cyclodextrin nanocarrier. Int. J. Nanomed. 2015, 10, 3147-3162.
DOI Google Scholar
21

Iyer, A. K.; Singh, A.; Ganta, S.; Amiji, M. M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv. Drug Deliv. Rev. 2013, 65, 1784-1802.
DOI Google Scholar
22

Xu, W. G.; Ding, J. X.; Xiao, C. S.; Li, L. Y.; Zhuang, X. L.; Chen, X. S. Versatile preparation of intracellular-acidity- sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic. Biomaterials 2015, 54, 72-86.
DOI Google Scholar
23

Yang, F.; Teves, S. S.; Kemp, C. J.; Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta-Rev. Cancer 2014, 1845, 84-89.
DOI Google Scholar
24

O'Brien, M. E. R.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P. et al. Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HCl (CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15, 440-449.
DOI Google Scholar
25

Han, M.; Lv, Q.; Tang, X. J.; Hu, Y. L.; Xu, D. H.; Li, F. Z.; Liang, W. Q.; Gao, J. Q. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J. Control. Release 2012, 163, 136-144.
DOI Google Scholar
26

Anuchapreeda, S.; Leechanachai, P.; Smith, M. M.; Ambudkar, S. V.; Limtrakul, P. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 2002, 64, 573-582.
DOI Google Scholar
27

Lu, W. D.; Qin, Y.; Yang, C.; Li, L. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics 2013, 68, 694-701.
DOI Google Scholar
28

Ganta, S.; Amiji, M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharmaceutics 2009, 6, 928-939.
DOI Google Scholar
29

Fernandez, A. M.; van Derpoorten, K.; Dasnois, L.; Lebtahi, K.; Dubois, V.; Lobl, T. J.; Gangwar, S.; Oliyai, C.; Lewis, E. R.; Shochat, D. et al. N-succinyl-(β-alanyl-L- leucyl-L-alanyl-L-leucyl)doxorubicin:  An extracellularly tumor- activated prodrug devoid of intravenous acute toxicity. J. Med. Chem. 2001, 44, 3750-3753.
DOI Google Scholar
30

Malhotra, M.; Tomaro-Duchesneau, C.; Prakash, S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 2013, 34, 1270-1280.
DOI Google Scholar
31

Song, X. J.; Wu, H.; Li, S.; Wang, Y. F.; Ma, X. J.; Tan, M. Q. Ultrasmall chitosan-genipin nanocarriers fabricated from reverse microemulsion process for tumor photothermal therapy in mice. Biomacromolecules 2015, 16, 2080-2090.
DOI Google Scholar
32

Wang, H.; Ke, F. Y.; Mararenko, A.; Wei, Z. Y.; Banerjee, P.; Zhou, S. Q. Responsive polymer-fluorescent carbon nanoparticle hybrid nanogels for optical temperature sensing, near-infrared light-responsive drug release, and tumor cell imaging. Nanoscale 2014, 6, 7443-7452.
DOI Google Scholar
33

Lin, S.; Li, T.; Xie, P. L.; Li, Q.; Wang, B. L.; Wang, L.; Li, L. L.; Wang, Y. Q.; Chen, H.; Nan, K. H. Targeted delivery of doxorubicin to tumour tissues by a novel legumain sensitive polygonal nanogel. Nanoscale 2016, 8, 18400-18411.
DOI Google Scholar
34

Lou, S. F.; Gao, S.; Wang, W. W.; Zhang, M. M.; Zhang, J.; Wang, C.; Li, C.; Kong, D. L.; Zhao, Q. Galactose- functionalized multi-responsive nanogels for hepatoma- targeted drug delivery. Nanoscale 2015, 7, 3137-3146.
DOI Google Scholar
35

Choi, K. Y.; Yoon, H. Y.; Kim, J. H.; Bae, S. M.; Park, R. W.; Kang, Y. M.; Kim, I. S.; Kwon, I. C.; Choi, K.; Jeong, S. Y. et al. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy. ACS Nano 2011, 5, 8591-8599.
DOI Google Scholar
36

Oommen, O. P.; Garousi, J.; Sloff, M.; Varghese, O. P. Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: An alternative to prodrug approach. Macromol. Biosci. 2014, 14, 327-333.
DOI Google Scholar
37

Liu, L.; Sun, L.; Wu, Q. J.; Guo, W. H.; Li, L. C.; Chen, Y. S.; Li, Y. C.; Gong, C. Y.; Qian, Z. Y.; Wei, Y. Q. Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis. Int. J. Pharm. 2013, 443, 175-182.
DOI Google Scholar
38

Soiberman, U.; Kambhampati, S. P.; Wu, T.; Mishra, M. K.; Oh, Y.; Sharma, R.; Wang, J. X.; Al Towerki, A. E.; Yiu, S.; Stark, W. J. et al. Subconjunctival injectable dendrimer- dexamethasone gel for the treatment of corneal inflammation. Biomaterials 2017, 125, 38-53.
DOI Google Scholar
39

Camacho, K. M.; Kumar, S.; Menegatti, S.; Vogus, D. R.; Anselmo, A. C.; Mitragotri, S. Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. J. Control. Release 2015, 210, 198-207.
DOI Google Scholar
40

Kabachinski, G.; Schwartz, T. U. The nuclear pore complex-structure and function at a glance. J. Cell Sci. 2015, 128, 423-429.
DOI Google Scholar
41

Vollmar, F.; Hacker, C.; Zahedi, R. P.; Sickmann, A.; Ewald, A.; Scheer, U.; Dabauvalle, M. C. Assembly of nuclear pore complexes mediated by major vault protein. J. Cell Sci. 2009, 122, 780-786.
DOI Google Scholar
42

Thiyagarajan, S.; Thirumalai, K.; Nirmala, S.; Biswas, J.; Krishnakumar, S. Effect of curcumin on lung resistance- related protein (LRP) in retinoblastoma cells. Curr. Eye Res. 2009, 34, 845-851.
DOI Google Scholar
43

Mosafer, J.; Teymouri, M.; Abnous, K.; Tafaghodi, M.; Ramezani, M. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells. Mater. Sci Eng. C 2017, 72, 123-133.
DOI Google Scholar
44

Sahay, G.; Kim, J. O.; Kabanov, A. V.; Bronich, T. K. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials 2010, 31, 923-933.
DOI Google Scholar
45

Rejinold, N. S.; Chennazhi, K. P.; Tamura, H.; Nair, S. V.; Rangasamy, J. Multifunctional chitin nanogels for simultaneous drug delivery, bioimaging, and biosensing. ACS Appl. Mater. Interfaces 2011, 3, 3654-3665.
DOI Google Scholar
46

Chen, Y. H.; Wang, C. C.; Xiao, X.; Wei, L.; Xu, G. X. Multidrug resistance-associated protein 1 decreases the concentrations of antiepileptic drugs in cortical extracellular fluid in amygdale kindling rats. Acta Pharmacol. Sin. 2013, 34, 473-479.
DOI Google Scholar
47

Perkins, S.; Verschoyle, R. D.; Hill, K.; Parveen, I.; Threadgill, M. D.; Sharma, R. A.; Williams, M. L.; Steward, W. P.; Gescher, A. J. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemol. Biomarkers Prev. 2002, 11, 535-540.
Google Scholar
48

Coccolini, F.; Acocella, F.; Morosi, L.; Brizzola, S.; Ghiringhelli, M.; Ceresoli, M.; Davoli, E.; Ansaloni, L.; D'Incalci, M.; Zucchetti, M. High penetration of paclitaxel in abdominal wall of rabbits after hyperthermic intraperitoneal administration of nab-paclitaxel compared to standard paclitaxel formulation. Pharm. Res. 2017, 34, 1180-1186.
DOI Google Scholar
49

Gong, C. Y.; Yang, B.; Qian, Z. Y.; Zhao, X.; Wu, Q. J.; Qi, X. R.; Wang, Y. J.; Guo, G.; Kan, B.; Luo, F. et al. Improving intraperitoneal chemotherapeutic effect and preventing postsurgical adhesions simultaneously with biodegradable micelles. Nanomed. Nanotechnol. Biol. Med. 2012, 8, 963-973.
DOI Google Scholar
50

Lopes, M.; Shrestha, N.; Correia, A.; Shahbazi, M. A.; Sarmento, B.; Hirvonen, J.; Veiga, F.; Seiça, R.; Ribeiro, A.; Santos, H. A. Dual chitosan/albumin-coated alginate/dextran sulfate nanoparticles for enhanced oral delivery of insulin. J. Control. Release 2016, 232, 29-41.
DOI Google Scholar
51

Allen, T. M.; Cullis, P. R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818-1822.
DOI Google Scholar
52

De Cock, L. J.; De Koker, S.; De Geest, B. G.; Grooten, J.; Vervaet, C.; Remon, J. P.; Sukhorukov, G. B.; Antipina, M. N. Polymeric multilayer capsules in drug delivery. Angew. Chem., Int. Ed. 2010, 49, 6954-6973.
DOI Google Scholar
53

de la Rica, R.; Aili, D.; Stevens, M. M. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Deliv. Rev. 2012, 64, 967-978.
DOI Google Scholar
54

Rao, W.; Wang, H.; Han, J. F.; Zhao, S. T.; Dumbleton, J.; Agarwal, P.; Zhang, W. J.; Zhao, G.; Yu, J. H.; Zynger, D. L. et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano 2015, 9, 5725-5740.
DOI Google Scholar
55

Muzzarelli, R. A. A.; Mattioli-Belmonte, M.; Miliani, M.; Muzzarelli, C.; Gabbanelli, F.; Biagini, G. In vivo and in vitro biodegradation of oxychitin-chitosan and oxypullulan-chitosan complexes. Carbohyd. Polym. 2002, 48, 15-21.
DOI Google Scholar
56

Ding, J. X.; Shi, F. H.; Xiao, C. S.; Lin, L.; Li, C.; He, C. L.; Zhuang, X. L.; Chen, X. S. One-step preparation of reduction- responsive poly(ethylene glycol)-poly(amino acid)s nanogels as efficient intracellular drug delivery platforms. Polym. Chem. 2011, 2, 2857-2864.
DOI Google Scholar
57

Yoon, H. H.; Shi, Q.; Sukov, W. R.; Wiktor, A. E.; Khan, M.; Sattler, C. A.; Grothey, A.; Wu, T. T.; Diasio, R. B.; Jenkins, R. B. et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin. Cancer Res. 2012, 18, 546-554.
DOI Google Scholar
58

Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
DOI Google Scholar
59

Baker, M. Deceptive curcumin offers cautionary tale for chemists. Nature 2017, 541, 144-145.
DOI Google Scholar
60

Nelson, K. M.; Dahlin, J. L.; Bisson, J.; Graham, J.; Pauli, G. F.; Walters, M. A. The Essential medicinal chemistry of curcumin. J. Med. Chem. 2017, 60, 1620-1637.
DOI Google Scholar
61

Heger, M. Drug screening: Don't discount all curcumin trial data. Nature 2017, 543, 40.
DOI Google Scholar
62

Jaroonwitchawan, T.; Chaicharoenaudomrung, N.; Namkaew, J.; Noisa, P. Curcumin attenuates paraquat-induced cell death in human neuroblastoma cells through modulating oxidative stress and autophagy. Neurosci. Lett. 2017, 636, 40-47.
DOI Google Scholar
File
12274_2017_1928_MOESM1_ESM.pdf (2.3 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 29 August 2017
Revised: 16 November 2017
Accepted: 19 November 2017
Published: 02 August 2018
Issue date: July 2018

Copyright

© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2017

Acknowledgements

Acknowledgements

The authors acknowledge the National Natural Science Foundation of China (No. 31600807), the Natural Science Foundation of Zhejiang Province (No. LQ15H120003), the National Key Research and Development Plan Project (No. 2016YFC1101201), and the Science and Technology Planning Project of Wenzhou City (No. Y20160085) for their financial support.

Return